Promega Corporation

Automation of Multiplexed Cell-Based Viability and Cytotoxicity Assays Scientific Poster

Share

SEARCH POSTERS

Abstract

Andrew Niles, Tracy Worzella and Michael Busch1
Promega Corporation, 2800 Woods Hollow Rd., Madison, WI 53711
1CyBio AG, Goeschwitzer Strasse 40, 07745 Jena, Germany 

Promega has developed homogeneous, non-lytic reagents that measure the proportion of viable and non-viable cells in the same assay well. Here we demonstrate the use of automation to perform highthroughput and ultra-high throughput cell-based multiplexing studies. We provide protocols and supporting data that demonstrate the automation synergies of the assays with the CyBio CyBi®-Well hardware. We show that complementary viability and cytotoxicity measures have particular merit for normalizing data to reduce error associated with cell clumping or identifying errors from interferences due to test compounds or medium components. In addition, we also demonstrate how the MultiTox assays can be further multiplexed with a downstream assay, such as a Promega luminescent assay or other spectrally distinct fluorescent assay method, to measure caspase activation, reporter activity, or cell viability. Specifically, we show how these novel assays can be further multiplexed with downstream apoptosis assays in order to determine mode of action effects.

Document Icon Download the poster PDF (142kb)

  • Part# PS070
  • Printed in USA.

Prefer a different language?

Your country is set to France. Your language is set to français. Please select the language that will best suit your needs:

This is correct, continue to site »

I need additional help

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.